China, Sept. 24 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Sacituzumab Tirumotecan for Patients with Pretreated Neuroendocrine Carcinoma: a single-center, single-arm, phase 2 trial.'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600133243
Registration Time: 2026/09/23
Type: Interventional study
Primary Sponsor: Sun Yat-sen University Cancer Center
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=344565
Published by HT Digital Content Services with permission from Health Daily Digest....